Post-authorization safety study (PASS)
Showing 1 - 25 of >10,000
Avacostar - (PASS)
Not yet recruiting
- ANCA-associated Vasculitis
- (no location specified)
Jun 12, 2023
A Non-Interventional Post-Authorization Study of Carbaglu for
Enrolling by invitation
- Hyperammonemia
- +2 more
- carglumic acid
-
Indianapolis, IndianaRiley Children's Hospital
Apr 24, 2023
Carbaglu® for Treatment of MMA and PA in Adults and Pediatrics
Recruiting
- Hyperammonemia
- +2 more
- Carglumic Acid
-
Washington, District of Columbia
- +1 more
Jun 30, 2022
Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With
Active, not recruiting
- Diabetes Mellitus, Type 2
- empagliflozin
- Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
-
Ingelheim am Rhein, GermanyBoehringer Ingelheim International GmbH
Aug 19, 2022
Use of Aflibercept Injections Into Eye for Treatment of Eye
Recruiting
- Retinal Disease
- Aflibercept (BAY86-5321, Eylea)
-
Multiple Locations, MexicoMany locations
Aug 22, 2022
A NIS of Alpelisib in Combination With Fulvestrant in
Not yet recruiting
- Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
- Alpelisib
- Fulvestrant
- (no location specified)
Aug 9, 2022
Assessment of Pregnancy Outcomes in Patients Treated With
Recruiting
- Multiple Sclerosis
- Siponimod
-
La Jolla, CaliforniaNovartis Investigative Site
Jan 20, 2023
Post Authorization Safety Study Moderna COVID-19 Primary Vaccine
Completed
- COVID-19
- Moderna COVID-19 Vaccine
-
Jakarta Pusat, Jakarta, Indonesia
- +17 more
Aug 22, 2023
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)
Completed
- Hemophilia A
- Congenital Factor VIII (FVIII) Deficiency
- Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]
-
BORDEAUX Cedex, France
- +16 more
Mar 15, 2021
A Prospective, Non-interventional, Long-term, Post-Authorisation
Not yet recruiting
- Growth Hormone Deficiency
- No intervention
- (no location specified)
Mar 8, 2023
Malignancy in Severe Asthma Patients Receiving Benralizumab and
Recruiting
- Asthma
- Neoplasms
-
Stockholm, Sweden
- +1 more
Aug 8, 2022
Primary Hemophagocytic Lymphohistiocytosis Trial in China (Emapalumab-Lzsg 5 MG/ML [Gamifant])
Recruiting
- Primary Hemophagocytic Lymphohistiocytosis
- Emapalumab-Lzsg 5 MG/ML [Gamifant]
-
Shanghai, Fudan, China
- +6 more
Feb 23, 2023
Characterize Effectiveness and Safety of HEMGENIX® in Hemophilia
Not yet recruiting
- Hemophilia B
- HEMGENIX
- Factor IX (FIX)
- (no location specified)
Aug 23, 2023
PASS of Paediatric Patients Initiating Selumetinib
Recruiting
- Neurofibromatosis Type 1
-
Angers, France
- +3 more
Jan 12, 2023
A Post-Authorization, Long-term Study of Ozanimod Real-world
Active, not recruiting
- Multiple Sclerosis, Relapsing-Remitting
-
Bethesda, MarylandEvidera
Oct 31, 2022
Prospective, Non-interventional, Multi-center Post-authorization
Recruiting
- Hypertension, Pulmonary
- Riociguat (ADEMPAS, BAY63-2521)
-
Multiple Locations, Japan(unnamed)
Jan 10, 2023
Kesimpta (Ofatumumab) Pregnancy Registry
Recruiting
- Multiple Sclerosis
- Pregnancy
- Kesimpta
-
La Jolla, CaliforniaNovartis Investigative Site
Jan 16, 2023
Prospective, Non-interventional, Multi-center,
Recruiting
- Hypertension, Pulmonary
- Riociguat (ADEMPAS, BAY63-2521)
-
Multiple Locations, JapanMany Locations
Aug 17, 2022
Leukemia/Lymphoma Trial in Milwaukee
Active, not recruiting
- Leukemia/Lymphoma
-
Milwaukee, WisconsinCIBMTR
Nov 17, 2021
Prospective, Non-interventional, Post-authorization Safety Study
Active, not recruiting
- Thyroid Carcinoma
- Sorafenib (Nexavar, BAY43-9006)
-
Multiple Locations, Japan(unnamed)
Aug 18, 2022
Patients on Waiting List for Surgery Due to Disc Herniation:
Active, not recruiting
- Lumbar Herniated Disc
-
Las Palmas De Gran Canaria, Las Palmas, SpainDr. Negrin University Hospital
Apr 1, 2022
MDR EZ Pass and Precision Flexible Reamer
Enrolling by invitation
- Anterior Cruciate Ligament Injury
- Rotator Cuff Tear
- EZ Pass Suture Passer
-
Charlotte, North CarolinaOrthoCarolina
Mar 17, 2022